10/10/2025

Janusmed sex and gender

Janusmed sex and gender – bortezomib

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Bortezomib

Bortezomib

Class : A

Show all info

Print

Contact us

  1. Velcade (bortezomib). DailyMed [www]. US National Library of Medicine. [updated 2025-08-28, cited 2025-08-17].

  2. Velcade (bortezomib). Summary of Product Charateristics. European Medicines Agency [updated 2024-05-01, cited 2025-08-17]

  3. Djebbari F, Srinivasan A, Vallance G, Moore S, Kothari J, Ramasamy K. Clinical outcomes of bortezomib-based therapy in myeloma. PLoS One. 2018;13(12):e0208920.

  4. Liu WN, Chang CF, Chung CH, Chien WC, Huang TC, Wu YY et al. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis. PLoS One. 2019;14(9):e0222522.

  5. Mauermann M, Dispenzieri A, and Staff N . The Clinical Spectrum of Bortezomib-Induced Peripheral Neuropathy [abstract]. Neurology. 2012;78 (Number 1 supplement).

  6. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1):23-31.

  7. Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T et al. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs. 2010;21(9):877-81.

  1. Velcade (bortezomib). DailyMed [www]. US National Library of Medicine. [updated 2025-08-28, cited 2025-08-17].
  2. Velcade (bortezomib). Summary of Product Charateristics. European Medicines Agency [updated 2024-05-01, cited 2025-08-17]
  3. Djebbari F, Srinivasan A, Vallance G, Moore S, Kothari J, Ramasamy K. Clinical outcomes of bortezomib-based therapy in myeloma. PLoS One. 2018;13(12):e0208920.
  4. Liu WN, Chang CF, Chung CH, Chien WC, Huang TC, Wu YY et al. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis. PLoS One. 2019;14(9):e0222522.
  5. Mauermann M, Dispenzieri A, and Staff N . The Clinical Spectrum of Bortezomib-Induced Peripheral Neuropathy [abstract]. Neurology. 2012;78 (Number 1 supplement).
  6. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86(1):23-31.
  7. Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T et al. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs. 2010;21(9):877-81.